WO1992013563A1

WO1992013563A1 - Antitumoral preparation and method of making same

Info

Publication number: WO1992013563A1
Application number: PCT/RO1992/000024
Authority: WO
Inventors: Viktor Vladimirovich Keshelava; Anatoly Vasilievich Bushuev
Original assignee: Keshelava Viktor V; Bushuev Anatoly V
Priority date: 1991-01-31
Filing date: 1992-01-31
Publication date: 1992-08-20
Also published as: RU1837891C

Abstract

An antitumoral preparation consists of a radioactive nuclide 59Fe or a composition containing it and has a β-radioactivity of not less than 0.5 mc per one dose of the preparation. A method of making the proposed preparation consists in that iron or an iron-containing compound is subjected to the neutron flux until the β-radioactivity of said compound of no less than 0.5 mc is obtained after which the preparation is conditioned up to decay of the accompanying radioactive nuclides.

Description

ПΡΟΤИΒΟΟПУΧΟЛΞΒЫЛ ПΡΕПΑΡΑΤ й СПΟСΟБ ΕГΟ ПΟΙУЧΕΗИП

The area of technology 5 The missing invention is in the field of medicine, and more precisely, of a new device for the treatment and use of it.

PREVIOUS LEVEL OF TECHNOLOGY

10 The widespread use of drugs is in the manufacture of pharmaceuticals, which are diagnostic and medicinal products that are suitable for the treatment of ill health.

Diagnostic Radiopharmaceuticals

15 in medicine are used to study the biological features of malignant tumors, for the treatment of effective treatment, for the detection of cases and problems.

Among the therapeutic and radiopharmaceutical

20 researchers found the name ⁹⁰ γ, ³ ρ, ⁹⁸ Αи, ¹³¹ <τ. The ⁹⁰ gamma odonuclide is used to treat cataracts up to 3 cm, which are localized in both a simple and convenient cortex. The indicated preparation is delivered, dose 30 m. 3 ² ρ Find a name for the treatment of malignant

25 good results in each other, good repair. You are given access to a dose of I I have lost. ⁹⁸ And they are used for the treatment of malignant tumors. DISCONNECTING TANKS, LITTLE VESSELS, SURFACES. For I was 20 minutes. ¹³¹ ζ

30 years of thyrotoxicosis and metastasis of a hormonal activity of the thyroid gland. ΒΕΟDYAΤ πρeπaρaτ πeρορalnο or ΕnuτρiΕennο, dοza 3-150 mΚi. Improvement of the indicated treatment of the USA at the destruction of the pathogens of the path of radiation. The use of medical and pharmaceutical products is inexorably affected by the load on the body of a sick person, which is a result of the risk of harm due to business Indicated τπηητι: 2 have common effects (natural and allergic reactions, idiosis) and are subject to a limited scope of application. A minor value is added to the radiological purity - for the radionuclide present Ε

5 Radiopharmaceuticals Ε Necessary chemical products. All of the aforementioned shortcomings and technical complications of the radiotherapy of pharmaceutical products do not impair the implementation of the system.

10 Β The literature has accumulated material on the possibility of using iron preparations, including radionuclide 59 -? E, for diagnosis in oncology. It is known, for example, a method of research of an erythropoiesis, diagnosis of anemia with the aid of a radioactive

15 nucleus 59th. It is a beta, hammock-emitter with a transition period of 45.1 days. A radioactive nuclide in the form of iron chloride is introduced into the circle. Immediately after the disappearance of the radionuclide

from plasma, there is an activity of an eritrogenic tissue. Indicated

The 20th method allows the use of radionuclide ^59, which is only for diagnostic purposes.

goals. The use of a radioactive nuclide for medicinal purposes is not known.

DETAILED DESCRIPTION OF THE INVENTION 25 On the basis of the invention, the task of creating the ΗΟΕΟΓΟ

The product is equipped with a high efficiency and a wide range of applications, as well as the method of processing thereof.

Task ρeshena τem, chτο zayaΕLyaemy προτivοοπuχο- 30 left πρeπaρaτ, sοglasnο izοbρeτeniyu, πρedsτavlyaeτ sοbοy ρadiοaκτivnyO nuκlid ⁵⁹ of? E or sοdeρzhaschee egο sοedinenie and οbladaeτ aκτivnοsτyu β-radiation of at least 0.5 on mΚi οdnu dοzu πρeπaρaτa. It is predominantly used for the manufacture of a propellant product that provides 35 sulphate or contains a radiative active nuclide ⁵⁹ ? The method of receipt of the claimed product, according to the invention, is concluded in the same way, that iron or jelly - 3 - the disconnecting connection allows the inactivity of β-radiation to be achieved by at least 0.5 us- ing not to

5 active nuclides. In the case of iron-containing compounds, any type of pharmaceutical compound used, for example, a non-ferrous substance, is a non-ferrous substance. Previous

10 Use a lot of iron or sulfate. Targeted sοοbρaznο zhelezο or zhelezοsοdeρzhaschee sοedinenie ποd- veρgaτ vοzdeysτviyu ποτοκa neyτροnοΕ πlοτnοsτyu 5 * neyτροnοv w / kT _'with at least 12 τechenie chasοv. The claimed drug indicates a therapeutic effect

15 for all medical paths, as found methods. - paths of the process in the process of research, and also neglected. The inventive product shows the impact on and on the main cells circulating the short circuit and are potential sources of development of the metastasis.

20 The inventive product is effective in treatment, safety of use (long-term availability of small business), The declaration claimed by the company has

25 A wide area of application, may be used for the treatment of various malignant diseases, including the disease. the mammary gland, the testes, the matrices, the pulmonary artery, the lymphoma and the other

The product is manufactured by a simple technician, it is available

30 tupen, convenient for use (it is possible to use).

Best Εaρianτ οsuschesτΕleniya izοbρeτeniya claimed προτivοοπuχοlevy πρeπataτ πρedsτaε- lyaeτ sοbοy ρadiοaκτivny nuκlid 59Ρe or 35 sοdeρzha- present egο sοedinenie (πρedποchτiτelnο laκτaτ or sulfonic φaτ ρadiοnuκlida Ρe ⁵⁹⁾ and οbladaeτ aκτivnοsτyu β-radiation of at least 0.5:.: Κi nε οdnu dοzu πρеπаρзτε. - 4 - DISCLOSURE OF β-EMISSION OF APPLIANCES MAY BE CAREFULLY AVAILABLE FOR PERSONAL CONDITION. Take care of the inside

5 free basic application for the internal use of a medicinal form, for example, in the form of a table. In the case of an appliance, the maximum concentration in the pots and the canals is observed after 3 hours after application. Then it falls over and after 36 hours it is consumed in the background. Κаκ

10 is known from the literature, and in addition to the processing of iron, the iron is internally accumulated in various oxygen and lymph nodes. This is the basis for the treatment of the claimed product. Declared that they are working for all of them -

15 nizmu, accumulates in the patient tissue and metastasis, acting on them with Β-radiation. This allows the treatment effect to be achieved independently of the number of patients and the place of use of primary impairment, and the prevention and suppression of medication.

20 keys in the domestic and lymphatic sectors.

For the preparation of the claimed preparation, nuclear processes may be used for different types. Iron or iron compounds. in quality terms

25 Any pharmaceutical compounds of iron can be used, they allow the participation of a variety of different charges.

It is preferable to use neutral flow 5 ^g 10 neutral / cm • with at least

30 12 hours If you have a problem with the operation, you must be able to do so if you have to change the pay-off period for a longer time. Adequate radioactivity and operational stability of neutrality, duration of irradiation and iron content Ε ISDΗΟΜ system

35 degrees. Received as a result of the impact of the neutralization of the product discharges to the decay of the injuring substances. The efficacy of the doses is claimed - 5 - The cost, depends on the char- acter of the patient, the disease, the result of the loss of health and his general health condition.

The inventive preparation was tested in the clinic. 5 Treatment is indicated for 30 patients with various malignant diseases, including cancer of the mammary gland, ovaries, uterus, lung cancer, skin, lymphoma, and others.

Mostly, these are good facilities at the stage of the canyon, with 10 different emergency centers and multiple meta-paths to distant cannons and tanks.

The treatment was carried out in an individual mode, taking into account the age and general condition of the patient.

In the case of a satisfactory condition, the treatment of the patient is 15 ples I I pills the drug 2 times a day for 15 days. The treatment was repeated after I, 3, and 6 months.

In the case of a moderate severity of painful treatment, I received a first test I once a day after a similar period of 20 me.

After 3-4 days, immediately after the start of treatment, the pain disappeared in the majority of patients with pain, and the increased inflated nodes decreased. Patients were prevented from administering β drugs. 25 Indications for treatment of the claimed medication are severe liver injuries, injuries.

The most effective is the use of the claimed medication in patients with radiation-sensitive cancer (cancer of the small gland, lung is better).

The treatment with the claimed device may also be combined with the best treatment (before or after treatment).

For the best understanding of the present invention, the following 35 communication methods are described below for the purpose of receiving medical treatment and their clinical trials. - 6 -

Example I.

Τableτκi, sοdeρzhaschie 525 mg sulφaτa iron Ε οdnοy τableτκe, chτο sοοτveτsτvueτ 105 mg elemenτaρnοgο iron οbluchayuτ ποτοκοm neyτροnθΕ πlοτnοsτyu 5 "1C ¹

5 neutrals / cm. s for 24 hours Notice that I have a radioactive activity of a single sulphate tablet ^{59 *} _that makes up my second.

Received radiative active sulphate tablets ⁵⁹ days last for 3-4 days for the collapse of the compulsory

10 marching radionuclides. The result is a product that provides a distinctive radionuclide of ⁵⁹ days, which has the active function of I-radiation from a second device (one-time delivery). The level of radioactivity of the existing nuclides is negligible. Prepared for

15 items.

For example, 2.

The results, similar to those described in Example I, are obtained under conditions similar to Example I. Irradiation of 20 is carried out for 12 hours. Indicated Radiative Sustainability Table ⁵⁹ -? E 0.6 mi. The resulting preparation can withstand 4 days for the decay of the available nuclides.

Received a product that provides its own sulphate

25 radionuclide ⁵⁹ ze, having an activity of ^ 5 -radiation of 0.6MI per one tablet (dose) of the drug. No comorbid radionuclides have been identified. It is suitable for connection.

30 p

Compounds containing an anhydrous sulphate of ferrous iron of 256.2 mg are used in a single tablet, which consumes 80 mg of iron, which has been exempted.

35 24 hours Failure to do one of the sulphate tablets ⁵⁹ ]? E 0, δ my. The obtained product is maintained for 3 days. for ρpasade SΟSCH ^Τ - 7 - radionuclide. It receives a product that delivers its own sulpha, τ radionuclide ^{5 *} _e , which has an active β-radiation of 0.8 to one that does not receive a device. The preparation is πρ-5 is suitable for use.

Example 4.

Laptops containing 0.246 g of iron in a single tablet are made under conditions similar to those used

10 I, for 24 hours The resulting preparation can withstand 4 days for the decay of the corresponding radionuclides. Indicated RADIOACTIVITY OF ONE LAPTOP LABEL ⁵⁹ _? _e 0.5 mΚi. It receives a preparation that sells its own component of radionuclide ⁵⁹ ? E, having an active

fifteen

-Mi radiation at a single tablet (dose) of the medicine. No related radionuclides were detected. It is suitable for use.

Example 5.

20 Items similar to those specified in Example I are subject to conditions similar to those in I for 48 hours. Induced performance of a single sulphate tablet ⁵⁹ ^{i *} _e is 10 mi. The product is discharged for 5 days for the decay of the associated damage

25 people. They receive a preparation, which is a sulphate of radionuclide ^{59 *} ρ _e . possessing

radiation of 10 per one tablet (dose) of the medicine. The level of radioactivity of the existing nuclides is negligible. It is suitable for connection.

thirty

Example 6.

The product, which was obtained on the basis of I, was tested in a clinic. Patient C, 40 years old, was on treatment for the cancer of the breast of the mammary gland. Was προf-

35th day operation - removal of the large mammary gland and major treatment. Again, it was empty with a waste: a left milk: gland with metastases Ε the best sites (cervical, supraclavicular, parastherial from the other side, in the 7th ringing bell). The result is a better treatment without effect. The treatment by the sick claimed by the Republic of Bashkortostan. The drug was prescribed

5 πο I table 2 times Ε day Ε course 1.5 months. In the last few days, after the onset of treatment, the nodes disappeared, the tumor in the iron decreased. After I year, after a thorough treatment, the condition is more painful. Healing is not provided. The patient is in good condition

10 observation.

Next to p 7.

Sick Η. , 66 years old, diagnosed with ovarian cancer ΙU is a clinical group. The operation could not be performed in the 15th form due to the distribution of the process. Β The largest area is up to 30 cm in diameter, enlarged lymph nodes. We begin to treat the treatment by treating them as described in the first paragraph. The preparation was terminated on the first tablet 2 times a day for the first month. On the 2nd day of life, much 20 softened significantly. The treatment was completed after I and 3 months. After I, the year showed that the condition is more satisfactory.

Example 8.

25 sick Η. , 65 years old, diagnosed with malignancy of the salivary gland, condition after surgery - the disease is ill. The abnormal metastasis is intact (the whole neck and the anterior abdomen of the chest wall). Occurred during the course of the first year

30 treatment. Good metastases succeeded. The treatment is started by the treatment described in Example 4. The drug was prescribed for I tablet 2 times a day for I month. After 5 days, the metastases also diminished significantly, the pain disappeared. Indicated 2

35 courses of treatment with an interval of 6 months. After a year, the condition is satisfactory. - 9 - Pρimθρ 9.

Patient 3., 40 years old, diagnosed with a cancer of the FIRST FABRIC gland, a clinical group, extensive metastasis. There was no cure for the cure. Income 5 Chemotherapy, evacuation. The treatment did not have an effect. Syndrome of pain. Initially, treatment was given, described as follows I. The drug was prescribed for I table 2 times a day for the course of I gloss. The treatment was delayed with an interval of I and 3 months. After 8 months after the start of treatment, an operation was performed. Crash on the left. After 6 months after surgery. No relapse or metastasis was found.

Ρ ле ρ ρ 10.

15 Sick Κ., 40 years old, diagnosis: cancer of the mammary gland

• Operation: An expanded resection of the mammary gland. Сл After the treatment, the treatment was carried out by the applicant, described in the case of 3. The drug was prescribed for the first treatment.

20 2 p times per day for 15 days. See after 9 months. Relapse and metastasis were not found.

Deliberate use of the Applied Patient Treatments 25 uses for the treatment of various malignant diseases, malignant disease, ovarian disease,

Κροme uκazannοgο, the claimed πρeπaρaτ, οbladaya sποsοbnοsτyu ποdavleniya shlmuniτeτa, mοκeτ nayτi πρi- 30 Menenius for lengthening προdοlzhiτelnοsτi ΕyzhiΕaniya allοτρansπlanτanτοΕ, ποdavleniya τρansπlanτatsiοnnοgο tlmunπτeτa and for treatment ρyada imglunyχ zabοleΕany, Εκlyuchaya SΙSCHTS.

Claims

- 10 -ΦΟΡΜУΙΑ ИзΙΑШШ

1. An effective preparation, which is also applicable to you, is that it delivers the necessary information for you or your friend.

5 feedback and has an active 5-emission of at least 0.5 mine for one dose of the drug.

2. The direct injection device. I, χ a - ρaκ τ e ρi s from yuschy with I τem, chτο οn πρedsτav- lyaeτ sοbοy sulφaτ or laκτaτ ρadiοaκτivnοgο nuκlitsa.

10 ^ze ¥ e.

3. The method of receiving the product, which is charged by the fact that the iron or the iron is connected to the device, the device is in operation.

15 radiation of this material is not less than 0.5 mine, after which they have been treated, they are capable of decaying the corresponding radioactive nuclides.

4. The method of operation is in accordance with clause 3, which is due to the fact that, as a result of iron-containing soyement 20, they use iron or sulfate.

5. Good luck to you from π.π. 3-4, the result of which is that an iron or iron connection allows for the operation to be disconnected without a connection for 5 * connection

25 at least 12 hours